A new T-287C polymorphism in the 5' regulatory region of the tissue factor pathway inhibitor gene

Thrombosis and Haemostasis

Volumn 84, Issue 2, 2000, Pages 244-249

  Moatti, Didier ^a   Haidar, Bassam ^a   Fumeron, Frédéric ^d   Gauci, Laurent ^c   Boudvillain, Olivier ^c   Seknadji, Patrick ^c   Ollivier, Véronique ^a   Aumont, Marie Claude ^c   De Prost, Dominique ^a,b,d  

^a INSERM   (France)

^b HÔPITAL LOUIS MOURIER   (France)

^c Service de Cardiologie   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

Myocardial infarction; Polymorphism; Promoter; Tissue factor pathway inhibitor; Unstable angina

Indexed keywords

ANTIGEN; HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK;

EID: 0033854157     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614003     Document Type: Article

References (19)

1. Jude B, Agraou B, Mcfadden EP, Susen S, Bauters C, Lepelley P, Vanhaesbroucke C, Devos P, Cosson A, Asseman P. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina. Circulation 1994; 90: 1662-8.
2. Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, Takazoe K, Miyao Y, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999; 99: 2908-13.
3. Kaikita K, Takeya M, Ogawa H, Suefuji H, Yasue H, Takahashi K, Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999; 188: 180-8.
4. Caplice N, Mueske C, Kleppe L, Simari R. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 1999; 98: 1051-7.
5. Broze Jr GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12.
6. van der Logt CPE, Reitsma PH, Bertina RM. Intron-Exon Organization of the Human Gene Coding for the Lipoprotein-Associated Coagulation Inhibitor - The Factor-Xa Dependent Inhibitor of the Extrinsic Pathway of Coagulation. Biochemistry 1991; 30: 1571-7.
7. Girard TJ, Eddy R, Wesselschmidt RL, Macphail LA, Likert KM, Byers MG, Shows TB, Broze GJ. Structure of the Human Lipoprotein-Associated Coagulation Inhibitor Gene - Intro/exon Gene Organization and Localization of the Gene to Chromosome-2. J Biol Chem 1991; 266: 5036-41.
8. Tyson DR, Kuppuswamy MN, Broze Jr GJ, Bajaj SP. Revised DNA sequence of exon 1 and 5′ flanking region of the human tissue factor pathway inhibitor gene. Thromb Res 1993; 70: 269-73.
9. Petit L, Lesnik P, Dachet C, Hugou I, Moreau M, Chapman J, Rouis M. The promoter of human tissue factor pathway inhibitor gene: identification of potential regulatory elements. Thromb Res 1999; 95: 255-62.
10. Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999; 19: 2251-62.
11. Caplice N, Mueske C, Kleppe L, Peterson T, Broze GJ, Simari R. Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors. Circ Res 1998; 83: 1264-70.
12. Miyala T, Sakata T, Kumeda K, Uchida K, Tsushima M, Fujimura H. Kawasaki T, Kato H. C-399T polymorphism in the promoter region of human tissue factor pathway inhibitor (TFPI) gene does not change the plasma TFPI antigen level and does not cause venous thrombosis. Thromb Haemost 1998; 80: 345-6.
13. Moatti D, Seknadji P, Galand C, Poirier O, Fumeron F, Desprez S, Garbarz M, Dhermy D, Arveiler D, Evans A, Luc G, Ruidavets JB, Ollivier V, Hakim J, Aumont MC, De Prost D. Polymorphisms of the Tissue Factor Pathway Inhibitor (TFPI) Gene in Patients with Acute Coronary Syndromes and in Healthy Subjects: Impact of the V264M Substitution on Plasma Levels of TFPI. Arterioscler Thromb Vasc Biol 1999; 19: 862-9.
14. Bell G, Karam J, Rutter W. Polymorphic DNA region adjacent to the 5′ end of the human insulin gene. Proc Natl Acad Sci USA 1981; 78: 5759-63.
15. Bara L, Bloch ML, Zitoun D, Samama M, Collignon F, Frydman A, Uzan A, Bouthier J. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993; 69: 443-52.
16. Heinemeyer T, Chen X, Karas H, Kel AE, Kel OV, Liebich I, Meinhardt T, Reuter I, Schacherer F, Wingender E. Expanding the TRANSFAC database towards an expert system of regulatory molecular mechanism. Nucleic Acids Res 1999; 27: 318-22.
17. Lindahl A, Abildgaard U, Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991; 64: 155-68.
18. Kamikura Y, Wada H, Yamada A, Shimura M, Hiyoyama K, Shiku H, Tanigawa M, Nishikawa H, Yamada N, Isaka N, Nakano T, Kumeda K, Kato H. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol 1997; 55: 183-7.
19. Kokawa T, Enjyoji K, Kumeda K, Kamibuko Y, Harada-Shiha M, Koh H, Tsashima M, Yamamoto A, Kato H. Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI. Arterioscler Thromb Vasc Biol 1996; 16: 802-8.